Management
Erez AminovChairman and CEO
In August 2024, Mr. Aminov further expanded his leadership portfolio by becoming the Chairman and Chief Executive Officer of Telomir Pharmaceuticals. At Telomir, he continues to leverage his extensive industry experience to guide the company’s strategic direction. Telomir-1, one of the company’s key projects, is under investigation as a potential therapeutic intervention against age-related inflammatory conditions. The drug is being developed to protect stem cells by elongating and stimulating telomeres, thus sustaining their self-renewal.
Mr. Aminov's journey into the biotech sector began in September 2021 when he founded Locate Venture Corp., a strategy and investment consulting firm dedicated to advancing early-stage biotech startups. With over two decades of industry experience, he has adeptly navigated the complex challenges of the biotech sector, forged strategic alliances, and successfully guided startups toward sustainable growth. He holds a B.A. in Accounting from Touro University in New York, and his financial acumen and investment expertise, particularly in early-stage life sciences companies, make him an exceptional leader and a valuable asset in the biotech industry.
Michelle Yanez, MBAChief Financial Officer
Ms. Yanez earned her B.A. in Business Management from University South Florida and further distinguished her acumen with an MBA in Strategic Leadership from Rutgers School of Business, Cum Laude.
Itzchak Angel, PhDChief Scientific Advisor
Dr. Angel’s journey in the sciences began with his education at the Tel-Aviv University, where he earned his B. Sc, and M.Sc. degrees in Biology in 1979 and 1980, taking part in a special curriculum for outstanding students. He further studied at the Hamburg University, Germany, obtaining a Ph.D. in Neurochemistry in 1982. His postdoctoral research took him to the National Institute of Mental Health in Bethesda, Maryland, where he pursued his research in Neurobiology. For numerous years, he was Head of Pharmacology at Synthelabo (Sanofi-Aventis, Paris, France) where he participated in the research and development of drugs such as Xatral (alfuzosin), Ambien (zolpidem), and Mizollen (mizolastine). Some of Dr. Angel's previous executive roles include President and Chief Executive Officer of the stem-cell company Accellta (Haifa, Israel) and Vice President for Research and Development at Proteologics Ltd, Galmed Pharmaceuticals, and D-Pharm Biopharmaceuticals (Rehovot, Israel), where he was involved in research and advanced development in several areas such as stroke, epilepsy, Alzheimer’s’ Disease, Parkinson’s disease, metabolic disorders, psoriasis, and various cancers.
Dr. Angel has effectively established discovery, research, and development teams and projects, bringing several pharmaceutical drugs to market. As an excellent communicator and negotiator, Dr. Angel has led international projects and worked closely with high-profile regulatory, government, and industry leaders.
Dr. Angel is the author of over 100 book chapters, papers, abstracts, and patents. Outside of his professional work, he is a passionate painter, music lover, and avid traveler who speaks several languages.
Francis E. O'Donnell, Jr., MDSenior Advisor
He received his BA from Johns Hopkins University’s accelerated program and his MD from Johns Hopkins University School of Medicine, as well as his specialty and fellowship training. He is an inventor or co-inventor on over 40 US patents.